Regulatory and launch services that help biotech companies sell experimental drugs through new state right-to-try pathways.
State‑Level Fast Paths for Experimental Therapeutics
Montana’s new “right to try” law has just moved forward, and some say it can’t come soon enough. The state is aiming to become an experimental‑drug hub, creating a controversial new route to market that could spur a rush of regulatory, clinical and risk‑management middlemen.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ★☆☆☆☆ (1/5)
with both ★★★☆☆ (3/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Jul 31, 2026 MIT Technology Review: Montana’s new “right to try” law can’t come soon enough for some
- Jul 31, 2026 MIT Technology Review: Montana’s plan to become an experimental medical hub just pushed forward
